A Prognostic Model of Triple-Negative Breast Cancer Based on miR-27b-3p and Node Status
暂无分享,去创建一个
Songjie Shen | Q. Sun | X. Cui | X. Ren | Xiaojiang Cui | Xiao Zhang | S. Shen | Yidong Zhou | Xiao Zhang | Qiang Sun | Zhiyong Liang | Xinyu Ren | Huan Chen | Yidong Zhou | Huan-Wu Chen | Z. Liang
[1] George A Calin,et al. Prooncogenic factors miR-23b and miR-27b are regulated by Her2/Neu, EGF, and TNF-α in breast cancer. , 2013, Cancer research.
[2] Anthony Rhodes,et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. , 2010, Archives of pathology & laboratory medicine.
[3] John W M Martens,et al. Four miRNAs associated with aggressiveness of lymph node-negative, estrogen receptor-positive human breast cancer , 2008, Proceedings of the National Academy of Sciences.
[4] H. Feilotter,et al. An array-based analysis of microRNA expression comparing matched frozen and formalin-fixed paraffin-embedded human tissue samples. , 2008, The Journal of molecular diagnostics : JMD.
[5] Carme Camps,et al. microRNA-associated progression pathways and potential therapeutic targets identified by integrated mRNA and microRNA expression profiling in breast cancer. , 2011, Cancer research.
[6] Massimo Negrini,et al. Breast cancer metastasis: a microRNA story , 2008, Breast Cancer Research.
[7] C. Hudis,et al. Triple-negative breast cancer: an unmet medical need. , 2011, The oncologist.
[8] Thomas D. Schmittgen,et al. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. , 2001, Methods.
[9] C. Croce,et al. Integrated MicroRNA and mRNA Signatures Associated with Survival in Triple Negative Breast Cancer , 2013, PloS one.
[10] L. Esserman,et al. A multigene predictor of metastatic outcome in early stage hormone receptor-negative and triple-negative breast cancer , 2010, Breast Cancer Research.
[11] K. Struhl,et al. MiR-27b targets PPARγ to inhibit growth, tumor progression, and the inflammatory response in neuroblastoma cells , 2011, Oncogene.
[12] S. Narod,et al. Triple-Negative Breast Cancer: Clinical Features and Patterns of Recurrence , 2007, Clinical Cancer Research.
[13] Gianluca Bontempi,et al. Biological Processes Associated with Breast Cancer Clinical Outcome Depend on the Molecular Subtypes , 2008, Clinical Cancer Research.
[14] C. Sotiriou,et al. Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures , 2007, Breast Cancer Research.
[15] Debra L Winkeljohn. Triple-negative breast cancer. , 2008, Clinical journal of oncology nursing.
[16] Robin L. Jones,et al. Beyond triple-negative breast cancer: the need to define new subtypes , 2010, Expert review of anticancer therapy.
[17] Massimo Negrini,et al. Micromarkers: miRNAs in cancer diagnosis and prognosis , 2010, Expert review of molecular diagnostics.
[18] G. Hortobagyi,et al. Nodal status and clinical outcomes in a large cohort of patients with triple-negative breast cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] J. Hassell,et al. A Gene Signature for Predicting Outcome in Patients with Basal-like Breast Cancer , 2012, Scientific Reports.
[20] C. Perou,et al. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013 , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.
[21] Anthony Rhodes,et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. , 2006, Archives of pathology & laboratory medicine.
[22] Ian O Ellis,et al. Prognostic markers in triple‐negative breast cancer , 2007, Cancer.
[23] F. Ferrari,et al. A MicroRNA Targeting Dicer for Metastasis Control , 2010, Cell.
[24] C. Perou,et al. A custom microarray platform for analysis of microRNA gene expression , 2004, Nature Methods.
[25] Samuel Leung,et al. Basal-Like Breast Cancer Defined by Five Biomarkers Has Superior Prognostic Value than Triple-Negative Phenotype , 2008, Clinical Cancer Research.
[26] Kazuhiko Hayashi,et al. Systematic analysis of microRNA expression of RNA extracted from fresh frozen and formalin-fixed paraffin-embedded samples. , 2007, RNA.
[27] R. Vyzula,et al. MiR-34b is associated with clinical outcome in triple-negative breast cancer patients , 2012, Diagnostic Pathology.
[28] Jeremy J. W. Chen,et al. Unique MicroRNA signature and clinical outcome of cancers. , 2007, DNA and cell biology.
[29] Paul Ellis,et al. Dissecting the heterogeneity of triple-negative breast cancer. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[30] Qiong Shao,et al. MicroRNA miR-21 overexpression in human breast cancer is associated with advanced clinical stage, lymph node metastasis and patient poor prognosis. , 2008, RNA.
[31] D. Medina,et al. Re-evaluation of mammary stem cell biology based on in vivo transplantation , 2008, Breast Cancer Research.
[32] Wolfgang Heller,et al. Triple-negative breast cancer: therapeutic options. , 2007, The Lancet. Oncology.
[33] S. Bull,et al. Prognostic Effect of Basal-Like Breast Cancers Is Time Dependent: Evidence from Tissue Microarray Studies on a Lymph Node–Negative Cohort , 2008, Clinical Cancer Research.
[34] King-Jen Chang,et al. Molecular Characteristics and Metastasis Predictor Genes of Triple-Negative Breast Cancer: A Clinical Study of Triple-Negative Breast Carcinomas , 2012, PloS one.
[35] Annuska M. Glas,et al. The 70-gene signature as a response predictor for neoadjuvant chemotherapy in breast cancer , 2010, Breast Cancer Research and Treatment.
[36] Päivi Heikkilä,et al. Subtyping of Breast Cancer by Immunohistochemistry to Investigate a Relationship between Subtype and Short and Long Term Survival: A Collaborative Analysis of Data for 10,159 Cases from 12 Studies , 2010, PLoS medicine.
[37] Jack Cuzick,et al. Comparison of PAM50 risk of recurrence score with oncotype DX and IHC4 for predicting risk of distant recurrence after endocrine therapy. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[38] R. Bast,et al. The Roles of MicroRNAs in the Cancer Invasion-Metastasis Cascade , 2010, Cancer Microenvironment.
[39] C. Sotiriou,et al. Global MicroRNA Expression Profiling Identifies MiR-210 Associated with Tumor Proliferation, Invasion and Poor Clinical Outcome in Breast Cancer , 2011, PloS one.
[40] N. Kondo,et al. High expression of microRNA-210 is an independent factor indicating a poor prognosis in Japanese triple-negative breast cancer patients. , 2012, Japanese journal of clinical oncology.